NXTC
Price
$0.48
Change
-$0.00 (-0.00%)
Updated
Jun 3, 12:36 PM (EDT)
Capitalization
13.47M
58 days until earnings call
RARE
Price
$36.57
Change
+$0.43 (+1.19%)
Updated
Jun 3, 12:54 PM (EDT)
Capitalization
3.42B
58 days until earnings call
Interact to see
Advertisement

NXTC vs RARE

Header iconNXTC vs RARE Comparison
Open Charts NXTC vs RAREBanner chart's image
NextCure
Price$0.48
Change-$0.00 (-0.00%)
Volume$392
Capitalization13.47M
Ultragenyx Pharmaceutical
Price$36.57
Change+$0.43 (+1.19%)
Volume$1.3K
Capitalization3.42B
NXTC vs RARE Comparison Chart
Loading...
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NXTC vs. RARE commentary
Jun 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NXTC is a Buy and RARE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 03, 2025
Stock price -- (NXTC: $0.48 vs. RARE: $36.14)
Brand notoriety: NXTC and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NXTC: 42% vs. RARE: 106%
Market capitalization -- NXTC: $13.47M vs. RARE: $3.42B
NXTC [@Biotechnology] is valued at $13.47M. RARE’s [@Biotechnology] market capitalization is $3.42B. The market cap for tickers in the [@Biotechnology] industry ranges from $307.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RARE’s FA Score shows that 0 FA rating(s) are green whileNXTC’s FA Score has 1 green FA rating(s).

  • RARE’s FA Score: 0 green, 5 red.
  • NXTC’s FA Score: 1 green, 4 red.
According to our system of comparison, NXTC is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NXTC’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 6 bullish TA indicator(s).

  • NXTC’s TA Score: 5 bullish, 3 bearish.
  • RARE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, RARE is a better buy in the short-term than NXTC.

Price Growth

NXTC (@Biotechnology) experienced а -5.42% price change this week, while RARE (@Biotechnology) price change was +1.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.84%. For the same industry, the average monthly price growth was +5.87%, and the average quarterly price growth was +2.31%.

Reported Earning Dates

NXTC is expected to report earnings on Jul 31, 2025.

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+8.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.42B) has a higher market cap than NXTC($13.5M). RARE YTD gains are higher at: -14.096 vs. NXTC (-37.704). NXTC has higher annual earnings (EBITDA): -50.34M vs. RARE (-449.9M). RARE has more cash in the bank: 494M vs. NXTC (55.9M). NXTC has less debt than RARE: NXTC (4.91M) vs RARE (38.3M). RARE has higher revenues than NXTC: RARE (591M) vs NXTC (0).
NXTCRARENXTC / RARE
Capitalization13.5M3.42B0%
EBITDA-50.34M-449.9M11%
Gain YTD-37.704-14.096267%
P/E RatioN/AN/A-
Revenue0591M-
Total Cash55.9M494M11%
Total Debt4.91M38.3M13%
FUNDAMENTALS RATINGS
RARE vs NXTC: Fundamental Ratings
RARE
NXTC
OUTLOOK RATING
1..100
512
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
14
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8465
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NXTC's Valuation (14) in the Biotechnology industry is somewhat better than the same rating for RARE (78). This means that NXTC’s stock grew somewhat faster than RARE’s over the last 12 months.

NXTC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that NXTC’s stock grew similarly to RARE’s over the last 12 months.

NXTC's SMR Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that NXTC’s stock grew similarly to RARE’s over the last 12 months.

NXTC's Price Growth Rating (65) in the Biotechnology industry is in the same range as RARE (84). This means that NXTC’s stock grew similarly to RARE’s over the last 12 months.

NXTC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that NXTC’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NXTCRARE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
71%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
81%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 15 days ago
75%
Bullish Trend 12 days ago
77%
Declines
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 7 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
72%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
NXTC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RIBEX59.990.39
+0.65%
American Funds Invmt Co of Amer R2E
FAMDX25.79N/A
N/A
FAM Small Cap Institutional
SLGFX19.88N/A
N/A
SEI Large Cap Index F (SIMT)
AFEGX52.13N/A
N/A
American Century Large Cap Equity G
FLOWX18.69N/A
N/A
Fidelity Water Sustainability

NXTC and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NXTC has been loosely correlated with CYTK. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if NXTC jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NXTC
1D Price
Change %
NXTC100%
-2.46%
CYTK - NXTC
37%
Loosely correlated
+0.61%
ACET - NXTC
36%
Loosely correlated
+4.27%
ORMP - NXTC
33%
Poorly correlated
+1.71%
GOSS - NXTC
32%
Poorly correlated
+4.05%
PMVP - NXTC
30%
Poorly correlated
-0.14%
More

RARE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with COGT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then COGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+6.20%
COGT - RARE
52%
Loosely correlated
+3.13%
CRNX - RARE
51%
Loosely correlated
+4.49%
RVMD - RARE
50%
Loosely correlated
+3.17%
RNA - RARE
49%
Loosely correlated
+7.07%
DNLI - RARE
49%
Loosely correlated
+5.44%
More